Compare DexCom, Inc. (DXCM) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard Value Index Fund ETF — how do they compare? DexCom, Inc. trades at $77.92 (market cap $28.06B), while Vanguard Value Index Fund ETF trades at $218.41. The key difference: Vanguard Value Index Fund ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | VTV | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | — |
52-Week High | $89.53 | $220.51 |
52-Week Low | $54.84 | $175.51 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
The Vanguard Value ETF (VTV) trades at $218.14, showing minor daily weakness but maintaining strong year-to-date gains of 16% as investors rotate from growth to value stocks. Technical indicators present a mixed picture with bullish moving averages but neutral oscillators, while recent news highlights VTV's positioning as a defensive alternative to tech-heavy funds amid AI bubble concerns. The ETF's low 0.03% expense ratio and higher dividend yield compared to total market funds enhance its appeal for value-oriented investors.
VTV offers exposure to large-cap value stocks with minimal technology exposure (8-13%), positioning it well during market rotations away from expensive growth names. Key catalysts include Federal Reserve policy signals and continued value stock outperformance, while risks involve potential reversals in the growth-value rotation and broader market volatility affecting defensive positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
